baber/WOPTO huggingface dataset:
Patent NZ-332778-A (NZ)
Title: Cyclic peptides that are cell adhesion inhibiting compounds that inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen and mucosal addressin cell adhesion molecule-1
Inventor: DUTTA ANAND SWAROOP
IPC: C07K14/78
Filed: 1997-06-18
Abstract: Cyclic peptide of formula (I) where Xaa1 is selected from L-amino acids selected from Phe, Lys and Arg; D-amino acids selected from Phe and Met, the L- and D-amino acid optionally substituted on its 'alpha'-carbon or its 'alpha'-amino group with a C1-4alkyl group; and MeIle; Xaa2, Xaa3 and Xaa4 are respectively Leu, Asp and Val, optionally substituted on their 'alpha'-carbon or 'alpha'-amino group with a C1-4alkyl group; X1 is selected from D-amino acids selected from Ala, Phe, Arg, Lys, Trp, hArg(Et)2, Orn(CHMe2), Orn(Me2), Lys(CHMe2) and Arg(Pmc), optionally substituted on their 'alpha'-carbon or 'alpha'-amino group with a C1-4alkyl group; Formula (II); NH(CH2)5CO; and NH(CH2)2S(CH2)yCO, where y is 1 or 2; X2 is selected from D-amino acids selected from Ala, Arg, Lys, His, hArg(Et)2, Orn(CHMe2), and Orn(Me2), optionally substituted on their 'alpha'-carbon or 'alpha'-amino group with a C1-4alkyl group; NH(CH2)2SCH2CO; and NH(CH2)xCO, where x is 2 or 3; Xaa5 and Xaa6 are each independently a D-amino acid selected from Ala and Arg, optionally substituted on its 'alpha'-carbon or 'alpha'-amino group with a C1-4alkyl group; p is 0 or 1; and q is 0 or when p is 1, q is 0 or 1; or a salt thereof. The cyclic peptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 [VLA-4] (a4b1) and of mucosal addressin cell adhesion molecule -1 (MAdCAM-1) with integrin a4b7. They have therapeutic applications such as in rheumatoid arthritis, multiple sclerosis, asthma, psoriasis, inflammatory bowel disease and insulin-dependent diabetes.
Patent NZ-335942-A (NZ)
Title: Switching matrix for packet switching network with first switching stage includes shift network
Inventor: MA JIAN
IPC: H04L12/54
Filed: 1997-11-04
Abstract: A switching matrix for a packet-switched communications network includes: several input ports and output ports and several switch elements SE1 to SE5. The switch elements are arranged in multiple stages and connected with each other.  Each switch element has many inputs and outputs and each switch element routes a data packet present at its given input to at least one of its outputs on the basis of routing information (SRT) carried by the packet. In order to reduce internal blocking in the switch, each switch element in at least the first switching stage is formed by a routing element REi and a shift network element SHEi, connected in series with each other so that the ith output of the routing network element is connected to the ith input of the shift network element.  In this way each routing network element routes the data packets according to preset, fixed rules on the basis of the routing information carried by the data packet.  Each shift network element shifts the data packet present on its ith input to its jth output, where the indexes i and j are paired so that within a given time slot, all the values of j are different from each other within a given shift network element, and within a given time slot, a different value of j is assigned to each of the same-valued i's used in the different shift network elements.
Patent NZ-501168-A (NZ)
Title: Method and drilling apparatus coupled to a non-metallic body (e.g. PVC, nylon or acrylic) to reduced vibrations during operation
Inventor: TANKALA KANISHKA
IPC: B28D1/04
Filed: 1998-06-16
Abstract: A drill bit 10 is provided with a cylindrical body portion 24 fabricated from a plastic material. The body portion is fastened in concentric, end-to-end relation to a cylindrical cutter 12 fabricated from a metallic material and having an array of cutting elements 16 disposed thereon. The body portion and cutter are preferably tubular, wherein the cutting elements are disposed in an annular array, to facilitate core or crown drilling operations.
Patent NZ-503803-A (NZ)
Title: Layered absorbent article with a zoned basis weight
Inventor: ZENKER DAVID LOUIS
IPC: A61F13/49
Filed: 1998-10-08
Abstract: An absorbent article includes an absorbent core having multiple absorbent layers, wherein the absorbent layers interact in such a manner which preferentially locates absorbed liquid in an appointed, high saturation wicking layer. The localization of the liquid within this wicking layer increases the potential of this layer to move liquid through capillary action due to the higher saturation level and increased amount of liquid available. In additional aspects, at least one primary layer region can have a non-uniform, selectively zoned basis weight distribution. Particular configurations of the at least one primary layer region can be constructed with a target area of the primary layer region having a basis weight which is less than a basis weight of another non-target portion of the primary layer region.
Patent NZ-507814-A (NZ)
Title: Microwave-activated latent heat storage bodies containing a paraffin-based heat storage material and a hygroscopic material
Inventor: FIEBACK KLAUS
IPC: F28D20/02
Filed: 1999-03-18
Abstract: A microwave-activated latent heat storage body with a paraffin-based latent heat storage material.  The latent heat storage body contains a hygroscopic material and a carrier material which has capillary-like holding spaces in which the latent heat storage material is contained.
Patent NZ-508272-A (NZ)
Title: Vinyl acetate catalyst comprising metallic palladium and gold prepared with potassium aurate
Inventor: WANG TAO
IPC: C07C67/055
Filed: 1999-05-19
Abstract: Preparing a catalyst for the production of vinyl acetate by the reaction of ethylene, oxygen and acetic acid. This comprises impregnating a porous support, where the porous surfaces of contain a catalytically effective amount of pre-reduced palladium with a solution of potassium aurate which is reduces the potassium to a catalytically effective amount of metallic gold.
Patent NZ-516412-A (NZ)
Title: Retentate chromatography and protein chip arrays with applications in biology and medicine
Inventor: HUTCHENS T WILLIAM
IPC: G01N33/52
Filed: 1998-06-19
Abstract: Described is method for detecting a binding partner of a receptor-ligand pair comprising providing a probe which comprises a substrate which comprises an adsorbent attached to a surface of the substrate. The receptor or the ligand is bound to the adsorbent. The adsorbent bound receptor or the adsorbent bound ligand is then exposed to a sample containing the binding partner under conditions to allow binding between the receptor or the ligand and the binding partner and then detecting bound binding partner by laser desorption mass spectrometry. The receptor is a member selected from a nuclear receptor, a cytoplasmic receptor, ac ells surface receptor, a hormone receptor and an intracellular receptor. Also described is a method for detecting a genetic package containing a polynucleotide that encodes a polypeptide agent that specifically binds to a target adsorbent.
Patent NZ-516543-A (NZ)
Title: Video data in communication systems using a virtual retinal display with resolution dependant on eye position
Inventor: RITTER RUDOLF
IPC: H04N7/173
Filed: 1999-06-18
Abstract: The system (1) is related to the transmitting and displaying of video data and to a communication terminal (4) and an appropriate central video unit (2). Users can request and receive video data from the central video unit (2), using communication terminals (4), in particular, mobile communication terminals (4), via a telecommunication network (3), in particular, a mobile telephone network (3). Image signals corresponding to the received video data are projected onto the retina (51) of the user by a virtual retina display device (41) of the communication terminal (4), whereby the current eye positions of the user are determined in the communication terminal (4) and are transmitted to the central video unit (2). Said central video unit (2) comprises a video filter module (22) which filters the aforementioned video data before its transmission, based on the received current eye positions, in such a way that outer image areas corresponding to the video data, which are projected onto the retina (51) outside the fovea (511) have a lower resolution than the inner image areas corresponding to the video data, which are projected onto the fovea (511) of the retina (51). Accordingly, the filtered video data contains a smaller amount of data than unfiltered video data.
Patent NZ-521804-A (NZ)
Title: Waste outlet
Inventor: KNIGHT RODNEY PAUL
IPC: A47K1/14
Filed: 2002-10-07
Abstract: A waste outlet (1) comprising a bowl (2) having an outlet (3) connectable to a waste pipe, a grate (6) within the bowl (2) or outlet and gripping means by which the grate may be lifted from the bowl (2) or outlet (3), the periphery of the grate (6) being of a shape and size to wipe against the interior surface of the bowl (2) or outlet (3) as the grate (6) is moved thereacross.
Patent NZ-522767-A (NZ)
Title: Thalidomide and a topoisomerase inhibitor for the treatment of cancer
Inventor: ZELDIS JEROME B
IPC: A61K31/454
Filed: 2001-05-10
Abstract: A topoisomerase inhibitor, preferably SN-38 and thalidomide are used in synergistic amounts for the manufacture of a composition or kit for treating primary or metastatic cancer, preferably colon or rectal cancer, for increasing the safe and effective dosage of the topoisomerase inhibitor by reducing a dose-limiting adverse effect associated with the inhibitor or for increasing the therapeutic efficacy of the topoisomerase, with the proviso that the inhibitor is not irinotecan. Thalidomide is also used in the manufacture of a composition for reducing or preventing an adverse effect associated with the chemotherapy or radiation therapy, with the proviso that the adverse effect is not due irinotecan or for protecting a cancer patient from adverse effects associated with the administration of an anti-cancer drug. Also described are pharmaceutical compositions and dosage forms comprising synergistic amounts of thalidomide and a topoisomerase inhibitor.
Patent NZ-522844-A (NZ)
Title: PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
Inventor: FREEMAN GORDON
IPC: A61K48/00
Filed: 2001-06-28
Abstract: A method of identifying a compound which modulates T cell activation by an antigen to which the T cell is specific at a low and high antigen concentration and wherein the high antigen concentration is at least about 10-fold higher than the low antigen concentration comprises a) contacting a T cell expressing a PD-L2 target molecule with a test compound at a low antigen concentration; b) determining the ability of the test compound to modulate T cell proliferation or cytokine production at the low antigen concentration; c) contacting a T cell expressing a PD-L2 target molecule with the test compound at a high antigen concentration; and d) determining the ability of the test compound to modulate T cell proliferation or cytokine production at the high antigen concentration, thereby identifying a compound which modulates T cell activation at a low and high concentration. Preferably the PD-L2 target molecule is PD-1. Also described are methods for identifying a compound which overcomes a PD-1 mediated negative signal.
Patent NZ-524533-A (NZ)
Title: Test systems and the use thereof for identifying and characterizing compounds
Inventor: SAMSON-HIMMELSTJERNA GEORG VON
IPC: C12Q1/68
Filed: 2001-08-24
Abstract: A method for identifying substances with anthelmintic activity comprises bringing a host cell expressing the transmembrane receptor HC110-R (SEQ ID NO:2) into contact with a candidate compound and detecting an increase in the concentration of Ca2+ in the cell as result of the interaction thereby identifying a compound having anthelmintic activity. Alpha-latrotoxin can be used as an agonist of transmembrane receptor of helminths and as a nematicide. Also described are methods of identifying calcium channel blockers and host cells with the deposit numbers DSM ACC2464 and DSM ACC2465.
Patent NZ-530266-A (NZ)
Title: Encoded message reconstruction from partial detection
Inventor: KOLESSAR RONALD S
IPC: G10L25/51
Filed: 2002-08-28
Abstract: A method and system for reliably detecting encoded messages included in audio media data in varying acoustic environments, where only a portion of the predetermined message may have been received or detected.
Patent NZ-534810-A (NZ)
Title: Tip for a foam-in-place dispenser
Inventor: RUDDY HENRY J
IPC: B29K105/04
Filed: 2003-03-12
Abstract: A foam-in-place dispenser (10) and a porous tip (18) therefore having a frusto-conical face (48), wherein an outermost rim (56) of the tip extends beyond the discharge end of the dispenser.
Patent NZ-560289-A (NZ)
Title: Histone deacetylase enzymes
Inventor: DAVIDSON ALAN HORNSBY
IPC: C07D471/04
Filed: 2006-05-04
Abstract: Disclosed is a hydroxycarbamoyl compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, wherein R1 is a carboxylic acid group (-COOH), or an ester group, Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O),NR3- and wherein the remaining substituents are defined in the specification. Also disclosed is a composition comprising said compound and the use of said compound for the preparation of a composition for the treatment of for example cancer.
Patent NZ-562144-A (NZ)
Title: Spirocyclic heterocyclic derivatives and methods of their use
Inventor: DOLLE ROLAND E
IPC: A61K31/438
Filed: 2006-03-31
Abstract: Disclosed are spirocyclic chroman derivatives as represented by the general formula XXVIII, wherein D is phenyl, 2-hydroxy-phenyl or a pyridinyl moiety, all of which are para-substituted by K; K is carboxy (-COOH), -C(=O)-O-alkyl, -S(=O)2-N(alkyl)(alkyl), heteroaryl, alkylheteroaryl, aminocarbonyl (-C(=O)-NH2), or N-alkylaminocarbonyl (-C(=O)-NH(alkyl)); R23, R24, and R26 are each independently H or alkyl; p is 1 or 2; A2 and B2 are each H, or together form a double bond; and X2 is -CH2- or -O-; or a stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or N-oxide thereof. Also disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier and which optionally further comprises an opioid, an agent for the treatment of neuralgia/neuropathic pain, an agent for the treatment of depression, an agent for the treatment of incontinence, or an anti-Parkinson's agent.
Patent NZ-562969-A (NZ)
Title: Modifiers for gypsum slurries and method of using them
Inventor: LETTKEMAN DENNIS M
IPC: B32B1/04
Filed: 2006-06-13
Abstract: Disclosed herein is a gypsum slurry that includes water, calcium sulphate hemihydrate, a polycarboxylate dispersant and a modifier which is a phosphonate. The modifier is chemically configured to improve the efficacy of the polycarboxylate dispersant.
Patent NZ-565930-A (NZ)
Title: Wheelchair with a programmable operating parameter that can be selected in a programming mode
Inventor: PETERS DARRYL
IPC: G05B19/10
Filed: 2006-08-31
Abstract: A power driven wheelchair capable of setting or modifying a programmable parameter and a method associated with a power driven wheelchair for setting or modifying a programmable parameter are disclosed. The power driven wheelchair includes a user interface device adapted to operate in a programming mode; and a first storage device in operative communication with the user interface device with at least a portion designated for storage of a programmable operating parameter associated with operation of the power driven wheelchair. The user interface device is used to select the programmable operating parameter, select a value for the programmable operating parameter, and save the selected value for the programmable operating parameter in the portion of the first storage device, such that when the power driven wheelchair exits the programming mode, the programmable operating parameter is set to the selected value for operation of the wheelchair. Further disclosed is an apparatus associated with a power driven wheelchair for communicating a programmable parameter set including a user interface device associated with a power driven wheelchair and adapted to operate in a programming mode; a portable storage medium in operative communication with the user interface device with at least a portion designated for storage of one or more programmable parameter sets associated with operation of the power driven wheelchair; and a local storage device in operative communication with the user interface device with at least a portion designated for storage of one or more programmable parameter sets associated with operation of the power driven wheelchair. The user interface device is used to select one or more programmable parameter sets from the portable storage medium and save the selected programmable parameter sets to the local storage device or vice versa.
Patent NZ-574678-A (NZ)
Title: Method of production of transgenic avian using embryonic stem cells
Inventor: VALARCHE ISABELLE
IPC: A01K67/00
Filed: 2007-08-09
Abstract: A method for culturing avian embryonic stem (ES) cells that comprises the steps: (a) Suspending ES cells originating from the blastoderm disk of fertilised un-incubated avian egg(s) in a basal culture medium supplemented with animal serum and insulin-like growth factor-1 (IGF-1) and ciliary neurotropic factor (CNTF) as the sole growth factors; and (b) Seeding the suspension of ES cells obtained in (a) on a layer of feeder cells and further culturing the ES cells between 2-10 passages. The cells obtained in the method can further be used in methods of genetic modification and subsequently used to generate a genetically modified bird. The bird can be a chicken or a duck.
Patent NZ-576375-A (NZ)
Title: Metastin derivatives and use thereof
Inventor: ASAMI TAIJI
IPC: C07K14/47
Filed: 2007-10-24
Abstract: Disclosed is a metastin derivative represented by the formula XX0-XX2-XX3-XX4-XX5-T-XX9-XX10-NH2 wherein the substituents are as defined in the specification. Also disclosed is the use of the metastin derivative in the manufacture of an agent for suppressing cancer metastasis or growth, preventing/treating choriocarcinoma, hydatidiform mole, invasive mole, miscarriage, fetal hypoplasia, abnormal glucose metabolism, abnormal lipid metabolism or labor induction, preventing/treating hormone-dependent cancer, infertility, endometriosis, early puberty or myoma of the uterus, and for preventing/treating Alzheimer's disease, moderate cognitive impairment or autism. The metastin derivative is also used to manufacture a gonadotropic hormone secretagogue agent or a sex hormone secretagogue agent.
Patent NZ-581377-A (NZ)
Title: Connector for holding resilient tube between annular inner and outer portions with at least one being helical
Inventor: MOORE SIMON GARRY
IPC: F16L33/00
Filed: 2010-11-17
Abstract: A connector has a connecting head, typically to connect to a tap and annular inner and outer portions extending from the connecting head. Resilient tube, typically as garden hose, is pushed in the direction shown into an entry passage having width less than that of the tube wall thickness. One of the annular portions is of helical construction so that there is relative movement between portions allowing entry. However, when the tube is pulled in an opposite direction to that shown the portions bear further on the tube to restrict its removal from the connector.
Patent NZ-590878-A (NZ)
Title: Antimicrobial gel formulations comprising an halogenated amine compound dispersed in a poly(acrylic acid) water-swellable polymer
Inventor: WANG LU
IPC: A61K31/131
Filed: 2009-08-12
Abstract: 590878 Disclosed is a formulation comprising an halogenated amine compound of Formula (I), which is dispersed in a poly(acrylic acid) and/or a poly(ethylene oxide) water-swellable polymer and wherein the compound is 90% stable for at least 30 days at about 25 degrees C. Specific examples of compounds of Formula (I) include: N,N-dichloro-2,2-dimethyltaurine, N-chloro-2,2-dimethyltaurine, N-chloro-4-amino-4-phosphonobutyric acid, N,N-dichloro-leucine boronic acid; 3-(dichloroamino)-N,N-diethyl-N,3-dimethylbutan-1-aminium chloride; and 3-(dichloroamino)-N,N,N-triethyl-3-methylbutan-1-aminium chloride; The formulations are useful for the manufacture of a medicament for the treatment of an infection caused by a bacterial, a microbial, a sporal, a fungal or a viral activity.
Patent NZ-591175-A (NZ)
Title: Post brackets for connecting ground anchor pin and tensioning rod
Inventor: O'TOOLE LAWRENCE
IPC: E04H12/22
Filed: 2011-02-15
Abstract: Disclosed is a bracket for a post allowing additional anchoring to better secure the post in the ground. The bracket comprises a body configured to be located at the post with at least two primary projections extending out from the body and up to four secondary projections with a slot extending out from the body. Each primary projection is configured to receive and retain a ground securing pin and each secondary projection configured to receive and retain an end of a tensioning rod. When the bracket is secured at the post and a pin is received and retained in each primary projection, and when the post is viewed in end profile, adjacent pins in adjacent primary projections extend at a right angle to each other.
Patent NZ-592887-A (NZ)
Title: Hanger for hollow walls
Inventor: POLLAK ALEXANDRE
IPC: A47G1/20
Filed: 2009-11-18
Abstract: An anchoring system for use with hollow panels. The system includes an anchor member and a separate fixture, which are adapted to be mounted together. The anchor member includes an elongated element, such as a wire, adapted to be inserted into and partly through a hollow panel, such as a wall, and to bear against a rear surface of the panel. A front of the fixture defines a forwardly-facing groove and the anchor member is adapted to extend in the groove. The fixture is adapted to bear against a front surface of the panel for securing the anchoring system to the panel.
Patent NZ-593460-A (NZ)
Title: Imidazopyrazine syk inhibitors
Inventor: KROPF JEFFREY E
IPC: A61K31/535
Filed: 2009-12-07
Abstract: Abstract 593460 Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample. Compounds disclosed include: 1-(5-{ [6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino} pyridin-2-yl)-4-methylpiperidin-4-ol; N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-6-[4-(propan-2-yl)piperazin-1-yl]pyridin-3-amine; 6-{ 8-[(2-methoxypyridin-4-yl)amino]imidazo[1,2-a]pyrazin-6-yl} -3,4-dihydro-2H-1,4-benzoxazin-3-one; N-[6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]-1,3-benzothiazol-5-amine; And [(2R)-4-(5-{ [6-(1H-indazol-6-yl)imidazo[1,2-a]pyrazin-8-yl]amino} pyridin-2-yl)morpholin-2-yl]methanol,